Strategic News Watch — June 25, 2026
| Merck KGaA’s $11.3 billion swoop for Bio-Techne — its biggest deal since the 2015 Sigma-Aldrich buy — reopens the life-science-tools M&A window on a day when a U.S. Supreme Court win for Bayer and back-to-back FDA actions show how single rulings and label expansions are resetting biopharma valuations.
Today’s top developments:
|
What to Watch
- Merck KGaA–Bio-Techne close: Track antitrust clearance timelines and whether the deal pressures Thermo Fisher, Danaher, and other tools players to consolidate; new CEO Kai Beckmann’s early bet signals tools, not direct drug development, as the growth platform.
- Bayer’s litigation reset: With the Supreme Court preempting state-law failure-to-warn claims, watch how Bayer revises its glyphosate reserves and capital allocation, and whether the ruling drains the legal overhang that has weighed on its valuation for years.
- Medicare GLP-1 access opens July 1: Lilly’s Bridge program for oral Foundayo and injectable Zepbound lands the same week as its UK LillyDirect launch; watch whether Novo Nordisk answers with comparable Part D access as oral GLP-1s near market.
- Generative AI in radiology regulation: The Cognita and Aidoc breakthrough designations are among the first for generative AI in clinical imaging; watch how fast rivals file for similar status and whether the FDA formalizes a review framework for AI-drafted documentation.
- CDK4/6 lifecycle defense: Ibrance’s new HR+/HER2+ maintenance indication shows Pfizer extending the franchise against class competition and patent pressure; watch for further label moves across CDK4/6 inhibitors as originators defend mature revenue bases.
This brief highlights the edition’s top stories. Read the full June 25, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.